Investor Relations
December 2, 2008
20th Annual Piper Jaffray Health Care Conference
VIA (Nasdaq: VIAP) is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA’s lead candidate, VIA-2291, targets a significant unmet medical need of reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA’s pipeline of drug candidates includes other compounds to address additional potential causes of cardiovascular and metabolic disease, including high cholesterol, high triglycerides and insulin sensitization / diabetes.
Recent Releases
Dec 29, 2009
VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
Dec 3, 2009
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
